Edgewise Therapeutics, Inc.

As of October 31, 2025, Edgewise Therapeutics, Inc. shows a neutral trend with mixed signals, being mildly bullish on the weekly MACD and OBV, while underperforming year-to-date and over the past year compared to the S&P 500.

As of October 31, 2025, Edgewise Therapeutics, Inc. shows a neutral trend with mixed signals, being mildly bullish on weekly and monthly Dow Theory but mildly bearish on daily moving averages, while outperforming the S&P 500 recently but underperforming year-to-date and over the past year, suggesting a cautious approach.

As of October 31, 2025, Edgewise Therapeutics, Inc. shows a neutral trend with mixed signals, having underperformed the S&P 500 year-to-date and over the past year, but outperformed it over the last three years.

As of June 3, 2025, Edgewise Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 in the past week and month but underperformed year-to-date and over the past year.

As of June 3, 2025, the market trend is mildly bearish, influenced by daily moving averages and monthly MACD signals, despite some bullish indicators on the weekly timeframe.

Edgewise Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $41 million and a market cap of $1.52 billion. The company has no dividend yield and negative return on equity.

As of Jun 18, Edgewise Therapeutics, Inc. has a market capitalization of $1.524 billion, with net sales of $0.00 million and a net profit of -$146.09 million over the last four quarters. The company reported shareholder's funds of $459.22 million and total assets of $486.82 million as of Dec 24.